

EULAR 2026 Congress

June 3–6, 2026
London, UK



TOP ABSTRACTS

To help navigate the exciting content being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, June 3–6, 2026, London, UK, the Lupus Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in lupus.

EULAR 2026: Top abstracts in lupus

June 3–6, 2026

Oral presentations: Thursday, June 4

Abstract	Title	Presenter	Time (BST)
OP0219 View	DORIS Remission and LLDAS attainment after up to 12 months of real-world anifrolumab treatment: Interim results from the ASTER study	Marta Mosca	08:25–08:35
OP0220 View	The association of physical function with patient-reported outcomes in people with systemic lupus erythematosus	Mrinalini Dey	08:35–08:45
OP0221 View	Association of the Treatment Response Measure for SLE (TRM-SLE) renal response thresholds with long-term outcomes in patients with lupus nephritis	Kathryn Connelly	08:45–08:55
OP0222 View	Proteinuria underestimates intrarenal inflammation after 12 months of therapy in lupus nephritis: Interim results from the ReBioLup study	Ioannis Parodis	08:55–09:05
OP0223 View	Risk-stratified use of triple therapy in lupus nephritis based on EULAR 2025 prognostic factors	Hironari Hanaoka	09:05–09:15

Oral presentations: Friday, June 5

Abstract	Title	Presenter	Time (BST)
OP0335 View	Safety and efficacy of subcutaneous ianalumab (VAY736) post-B cell recovery in patients with systemic lupus erythematosus: End of study results from a phase 2 study	Edward M. Vital	08:15–08:25
OP0336 View	Obinutuzumab induces histological remission and deep kidney parenchymal B-cell depletion in patients with lupus nephritis: Exploratory analyses of the phase III REGENCY trial	Richard A. Furie	08:25–08:35
OP0337 View	Safety and efficacy of enpatoran in lupus: Results from the first 48 weeks of the phase II WILLOW long-term extension study	Eric Morand	08:35–08:45
OP0340 View	Safety and efficacy of daratumumab in treatment-refractory systemic lupus erythematosus: Results from the long-term extension of a phase 2 trial	Tobias Alexander	09:05–09:15
OP0341 View	Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (srSLE): Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results from the phase I CARLYSLE study	Maria Leandro	09:15–09:25
OP0342 View	Improved SLE disease activity across multiple organ systems after up to 12 months of real-world treatment with anifrolumab: Interim results from the ASTER study	Zahir Amoura	09:25–09:35

Oral presentations: Saturday, June 6

Abstract	Title	Presenter	Time (BST)
LB0006 View	Efficacy and safety of sirolimus in active systemic lupus erythematosus: A multicenter, double-blind, randomized, placebo-controlled trial	Liyong Peng	12:50–13:00
LB0007 View	Nipocalimab in SLE: First-in-class efficacy and safety results demonstrating proof of concept for FcRn blockade from the phase 2 JASMINE-SLE study	Richard A. Furie	13:00–13:10

Posters

Abstract	Title	Presenter	Date and time (BST)
POS0040 View	Less pronounced interferon signature in primary antiphospholipid syndrome compared with other autoimmune diseases	Dionysis Nikolopoulos	Wednesday, June 3, 15:48–15:54
POS0071 View	Efficacy of enpatoran on arthritis outcomes in participants with active cutaneous manifestations of SLE: A <i>post-hoc</i> analysis of Cohort B of the phase II WILLOW study	Eric Morand	Thursday, June 4, 09:30–09:36
POS0073 View	Anifrolumab versus belimumab in active systemic lupus erythematosus: A propensity score matched analysis	Filippo Vesentini	Thursday, June 4, 09:42–09:48
POS0075 View	Efficacy of subcutaneous anifrolumab across multiple organ systems in patients with moderate to severe systemic lupus erythematosus: A <i>post-hoc</i> analysis of the phase 3 TULIP-SC trial	Richard A. Furie	Thursday, June 4, 09:54–10:00
POS0077 View	Five-year safety of belimumab in SLE: Insights from the global, prospective, observational SABLE registry	Ronald F. van Vollenhoven	Thursday, June 4, 10:06–10:12
POS0683 View	The impact of obinutuzumab on remission and low disease activity in active systemic lupus erythematosus: Additional results of the phase III ALLEGORY trial	Richard A. Furie	Thursday, June 4, 15:10–15:20
POS0688 View	Obinutuzumab β (MIL62), a novel glycoengineered type II anti-CD20 antibody, for active lupus nephritis: 104-week results of a phase 1b/2 randomized, double-blind, placebo-controlled trial	Yuhui Li	Thursday, June 4, 18:30–18:40
POS0691 View	Real-world use of voclosporin in UK lupus nephritis patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)	Ian Bruce	Thursday, June 4, 13:20–13:30
POS0698 View	Safety and efficacy of rese-cel (resecabtagene autoleucel) in severe, refractory SLE and lupus nephritis: Results from the RESET-SLE clinical trial phase 1/2 cohorts	Christopher Palma	Thursday, June 4, 16:20–16:30

POS0701 View	Memantine improves neuropsychological function in systemic lupus erythematosus: Results from a phase II randomized, double-blind, placebo-controlled trial	Leslie Crofford	Thursday, June 4, 16:00–16:10
POS0712 View	An allogenic CD19 CAR NK cells (SNC-103) in patients with severe, refractory systemic lupus erythematosus: Preliminary efficacy and safety results	Yakai Fu	Thursday, June 4, 17:10–17:20
POS0713 View	Orelabrutinib, a highly selective inhibitor of Bruton's tyrosine kinase(BTK), for the treatment of systemic lupus erythematosus(SLE): Results of a randomized, double-blind, placebo-controlled, phase IIb study	Zhanguo Li	Thursday, June 4, 16:40–16:50
POS0714 View	Treatment with anifrolumab prevents organ damage accrual compared with real-world standard of care in patients with systemic lupus erythematosus: Analysis of the LASER study over 4 years	Zahi Touma	Thursday, June 4, 12:50–13:00
POS0721 View	Real-world effectiveness of anifrolumab in systemic lupus erythematosus: 12-month multicenter data	Daliya Pencheva	Thursday, June 4, 14:30–14:40
POS0730 View	Glucocorticoid-sparing maintenance of disease control in patients with systemic lupus erythematosus: 48-week results from a phase 3 trial of dapirolizumab pegol	Eric Morand	Thursday, June 4, 12:30–12:40
POS0732 View	Interleukin-18-secreting autologous CAR T-cells targeting CD19 and BCMA for refractory systemic lupus erythematosus	Qian Wang	Thursday, June 4, 14:50–15:00
POS1363 View	Impact of disease activity improvements on patient-reported outcomes in patients with systemic lupus erythematosus: Results from the phase 2 SLEek study	Chris Wincup	Saturday, June 6, from 10:15
POS1367 View	Improvement of neurological symptoms and associated biomarkers with deucravacitinib in patients with systemic lupus erythematosus in the phase 2 PAISLEY SLE trial	Marilyn Pike	Saturday, June 6, from 10:15
POS1368 View	Validation of EULAR targets at 3 and 6 months as predictors of complete renal response in lupus nephritis: Results from a real-life multicenter cohort	Maria Pappa	Saturday, June 6, from 10:15
POS1376 View	Cross-cohort international validation of treat-to-target endpoints in childhood lupus: Data from the UK JSLE cohort study, CARRA registry and JIR cohort	Eve Smith	Saturday, June 6, from 10:15
POS1379-HPR View	Patient-perceived symptom burden, psychological distress, quality of life, and frailty risk in systemic lupus erythematosus and antiphospholipid syndrome: Preliminary findings from the PETAL study	Sofia Magrin	Saturday, June 6, from 10:15



EULAR 2026

Follow us on X to keep up to date
with the latest from the congress

@Lupus_Hub



Brought to you by

